Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Q1 Earnings Review: Healthy Revenue Increases, Smaller Profit Growth

publication date: May 23, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
It's earnings season, and almost every day for the past few weeks, one to three China life science companies listed in the US have released their quarterly financial reports. Taken as a whole, companies from this sector have almost uniformly reported higher revenues. Net income has also risen, though usually by a lower percentage. The two largest companie in the groups, Mindray Medical and WuXi PharmaTech, continue to impress with strong gains. Price/Earnings ratios are lower than they were a few years ago, ranging from 31 down to a lowly 1.4. We give snapshots of the sixteen companies that have released reports so far this month. More details....

Stock Symbols: (NYSE: MR) (NYSE: WX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...